Publication Information

{'id': 'https://openalex.org/W4282916011', 'doi': 'https://doi.org/10.1158/1538-7445.am2022-3346', 'title': 'Abstract 3346: BBT-207, a novel, 4th generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with broad-spectrum activity to both treatment-emergent and drug-naïve mutants for the treatment of NSCLC', 'display_name': 'Abstract 3346: BBT-207, a novel, 4th generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with broad-spectrum activity to both treatment-emergent and drug-naïve mutants for the treatment of NSCLC', 'publication_year': 2022, 'publication_date': '2022-06-15', 'ids': {'openalex': 'https://openalex.org/W4282916011', 'doi': 'https://doi.org/10.1158/1538-7445.am2022-3346'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2022-3346', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5078506578', 'display_name': 'Taiguang Jimmy Jin', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Taiguang Jimmy Jin', 'raw_affiliation_strings': ['1Bridge Biotherapeutics, Inc., Cambridge, MA;'], 'affiliations': [{'raw_affiliation_string': '1Bridge Biotherapeutics, Inc., Cambridge, MA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5109805840', 'display_name': 'Sang-Uk Kang', 'orcid': None}, 'institutions': [], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Sang-Uk Kang', 'raw_affiliation_strings': ['2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5115591363', 'display_name': 'Chulwon Kim', 'orcid': None}, 'institutions': [], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Chulwon Kim', 'raw_affiliation_strings': ['2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5091424768', 'display_name': 'Jehrod Brenneman', 'orcid': 'https://orcid.org/0000-0001-6720-4508'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Jehrod Brenneman', 'raw_affiliation_strings': ['1Bridge Biotherapeutics, Inc., Cambridge, MA;'], 'affiliations': [{'raw_affiliation_string': '1Bridge Biotherapeutics, Inc., Cambridge, MA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5085419122', 'display_name': 'Mihee Song', 'orcid': None}, 'institutions': [], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Mihee Song', 'raw_affiliation_strings': ['2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5038759029', 'display_name': 'Pavel Printsev', 'orcid': None}, 'institutions': [], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Pavel Printsev', 'raw_affiliation_strings': ['2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5041075600', 'display_name': 'Bo‐Bae Seo', 'orcid': None}, 'institutions': [], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Bo-Bae Seo', 'raw_affiliation_strings': ['2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5100398118', 'display_name': 'Jeong Yong Lee', 'orcid': 'https://orcid.org/0000-0001-6689-2759'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Yong-Hee Lee', 'raw_affiliation_strings': ['1Bridge Biotherapeutics, Inc., Cambridge, MA;'], 'affiliations': [{'raw_affiliation_string': '1Bridge Biotherapeutics, Inc., Cambridge, MA;', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5100416609', 'display_name': 'Sang‐Yoon Lee', 'orcid': 'https://orcid.org/0000-0003-2595-505X'}, 'institutions': [], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Sang-Yoon Lee', 'raw_affiliation_strings': ['2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Bridge Biotherapeutics, Inc., Seongnam-si, Republic of Korea.', 'institution_ids': []}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 1.263, 'has_fulltext': False, 'cited_by_count': 5, 'citation_normalized_percentile': {'value': 0.999972, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 83, 'max': 85}, 'biblio': {'volume': '82', 'issue': '12_Supplement', 'first_page': '3346', 'last_page': '3346'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9921, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9921, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11287', 'display_name': 'Cancer Genomics and Diagnostics', 'score': 0.9828, 'subfield': {'id': 'https://openalex.org/subfields/1306', 'display_name': 'Cancer Research'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T11067', 'display_name': 'Colorectal Cancer Treatments and Studies', 'score': 0.9827, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/osimertinib', 'display_name': 'Osimertinib', 'score': 0.8143736}, {'id': 'https://openalex.org/keywords/t790m', 'display_name': 'T790M', 'score': 0.81285554}], 'concepts': [{'id': 'https://openalex.org/C2777626846', 'wikidata': 'https://www.wikidata.org/wiki/Q21506464', 'display_name': 'Osimertinib', 'level': 5, 'score': 0.8143736}, {'id': 'https://openalex.org/C2777930144', 'wikidata': 'https://www.wikidata.org/wiki/Q25100112', 'display_name': 'T790M', 'level': 5, 'score': 0.81285554}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.5879172}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.5824599}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.50951487}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.49355876}, {'id': 'https://openalex.org/C42362537', 'wikidata': 'https://www.wikidata.org/wiki/Q87099740', 'display_name': 'Tyrosine kinase', 'level': 3, 'score': 0.47794297}, {'id': 'https://openalex.org/C143065580', 'wikidata': 'https://www.wikidata.org/wiki/Q3285695', 'display_name': 'Mutant', 'level': 3, 'score': 0.44421792}, {'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.4178627}, {'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.34253633}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.33019271}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.2830336}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.21792144}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.18280563}, {'id': 'https://openalex.org/C54355233', 'wikidata': 'https://www.wikidata.org/wiki/Q7162', 'display_name': 'Genetics', 'level': 1, 'score': 0.15618959}, {'id': 'https://openalex.org/C104317684', 'wikidata': 'https://www.wikidata.org/wiki/Q7187', 'display_name': 'Gene', 'level': 2, 'score': 0.14223313}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2022-3346', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being', 'score': 0.84}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3147989365', 'https://openalex.org/W2947332762', 'https://openalex.org/W2887887720', 'https://openalex.org/W2769241338', 'https://openalex.org/W2418692205', 'https://openalex.org/W2280113021', 'https://openalex.org/W2254126652', 'https://openalex.org/W2168841302', 'https://openalex.org/W2015104488', 'https://openalex.org/W2015000811'], 'abstract_inverted_index': {'Abstract': [0], 'Background:': [1], 'Activating': [2], 'mutations': [3, 96, 375], 'in': [4, 14, 31, 156, 218, 236, 267, 305, 335, 389, 408], 'EGFR,': [5], 'e.g.,': [6], 'L858R': [7], '(L)': [8], 'and': [9, 19, 52, 137, 173, 188, 196, 202, 209, 223, 251, 253, 261, 281, 288, 295, 314, 339, 346, 378, 452], 'Del19': [10], '(D),': [11], 'are': [12, 97, 118], 'observed': [13, 321, 374], '14.1-32.3%': [15], 'of': [16, 38, 47, 76, 106, 127, 158, 331, 356, 376, 386, 398, 458, 463], 'NSCLC': [17, 459], 'worldwide': [18], 'defines': [20], 'a': [21, 35, 44, 77, 130, 143, 366, 433], 'druggable': [22], 'entity.': [23], 'Single': [24, 229], 'agent': [25], 'EGFR': [26, 55, 65, 132, 146, 190, 198, 247, 377, 399], 'TKI': [27, 133, 147], 'treatment': [28, 397, 457], 'was': [29, 41, 205, 216, 234, 265, 271, 311, 320, 326], 'established': [30], 'clinical': [32, 121, 167], 'trials.': [33], 'However,': [34], 'treatment-emergent': [36, 94, 136, 451], 'mutation': [37, 79], 'T790M': [39, 286], '(T)': [40], 'identified': [42], 'as': [43, 71, 273, 275], 'major': [45], 'source': [46], 'drug': [48, 348, 405], 'resistance.': [49], 'Irreversible': [50], '2nd': [51], '3rd': [53, 63], 'generation': [54, 64, 110, 145], 'TKIs': [56, 66, 86], 'were': [57, 200, 290, 341], 'shown': [58], 'effective.': [59], 'Mutant-specific': [60], 'inhibition': [61, 319], 'by': [62, 207, 293, 302, 328], 'reduced': [67], 'adverse': [68], 'events': [69], 'such': [70], 'skin': [72], 'toxicities.': [73], 'The': [74], 'emergence': [75, 126], 'missense': [78], 'at': [80, 297], 'C797': [81, 117], '(C),': [82], 'to': [83, 277, 308, 372, 381, 394, 449], 'which': [84, 164, 309, 325], 'irreversible': [85], 'covalently': [87], 'bind,': [88], 'limited': [89], 'their': [90], 'efficacy.': [91], 'Patients': [92], 'harboring': [93, 194], 'C': [95], 'left': [98], 'with': [99, 343, 354, 384, 446], 'few': [100], 'therapeutic': [101], 'options.': [102], 'Despite': [103], 'anecdotal': [104], 'reports': [105], 'efficacy': [107], 'from': [108, 162, 322], '1st': [109], 'TKIs,': [111], 'these': [112], 'complex': [113], 'molecular': [114], 'variants': [115], 'involving': [116], 'an': [119, 224], 'increasing': [120], 'concern.': [122], 'To': [123], 'prevent': [124], 'the': [125, 329, 351, 359, 396, 456, 464], 'drug-resistant': [128], 'subclones,': [129], 'broad-spectrum': [131, 369, 447], 'against': [134, 185, 246, 257], 'both': [135, 268, 450], 'drug-naïve': [138, 453], 'mutants': [139, 249, 259, 279, 284, 454], 'is': [140, 165, 365, 379, 392], 'required.': [141], 'Such': [142], '4th': [144, 435], 'must': [148], 'also': [149, 272], 'enable': [150], 'monotherapy,': [151], 'allowing': [152], 'precise': [153], 'dose': [154, 230], 'adjustment': [155], 'case': [157], 'toxicity.': [159], 'Method:': [160], 'Derived': [161], 'BBT-176': [163], 'under': [166], 'evaluation': [168], '(NCT04820023),': [169], 'we': [170, 182], 'synthesized': [171], 'BBT-207': [172, 239, 270, 294, 323, 364, 391], 'other': [174], 'related': [175], 'molecules.': [176], 'Using': [177], 'Promega': [178], 'ADP-Glo™': [179], 'kinase': [180, 443], 'assay,': [181], 'tested': [183], 'compounds': [184], 'wild-type': [186], '(WT)': [187], 'mutated': [189, 197, 400], 'proteins.': [191], 'Ba/F3': [192, 219], 'cells': [193], 'WT': [195], 'genes': [199], 'created': [201], 'cell': [203], 'viability': [204], 'measured': [206], 'CellTiter-Glo®': [208], 'SpectraMax': [210], 'iD3®.': [211], 'In': [212, 304], 'vivo': [213, 306], 'anti-tumor': [214], 'activity': [215, 448], 'evaluated': [217], 'cell-derived': [220], 'xenograft': [221, 227], 'models': [222, 307], 'Osimertinib-resistant': [225], 'patient-derived': [226], 'model.': [228], 'pharmacokinetic': [231], '(PK)': [232], 'study': [233], 'performed': [235], 'animals.': [237], 'Results:': [238], 'showed': [240], 'IC50': [241, 255, 352], 'values': [242, 256], '<': [243], '10': [244], 'nM': [245], 'triple': [248], '(DTC': [250], 'LTC)': [252], 'comparable': [254], 'double': [258], '(DC': [260], 'LC),': [262], 'while': [263, 300], 'Osimertinib': [264, 296, 310], 'ineffective': [266], 'groups.': [269], 'active': [274, 371], 'Gefitinib': [276], 'single': [278], '(D': [280], 'L).': [282], 'Double': [283], 'containing': [285], '(DT': [287], 'LT)': [289], 'inhibited': [291], 'effectively': [292], 'similar': [298], 'concentrations,': [299], 'not': [301], 'Gefitinib.': [303], 'inactive': [312], '(LC': [313], 'DTC),': [315], 'significant': [316], 'tumor': [317], 'growth': [318, 438], 'alone,': [324], 'enhanced': [327], 'addition': [330], 'Osimertinib.': [332], 'PK': [333], 'studies': [334], 'mouse,': [336], 'rat,': [337], 'dog': [338], 'monkey': [340], 'consistent': [342], 'high': [344], 'exposure': [345], 'sustained': [347], 'concentrations': [349], 'above': [350], 'values,': [353], 'evidence': [355], 'penetration': [357], 'into': [358], 'central': [360], 'nervous': [361], 'system.': [362], 'Conclusion:': [363], 'reversible,': [367], 'mutant-specific,': [368], 'TKI,': [370], 'clinically': [373], 'expected': [380], 'be': [382], 'compatible': [383], 'monotherapy': [385], 'QD': [387], 'schedule': [388], 'humans.': [390], 'well-positioned': [393], 'augment': [395], 'NSCLC,': [401], 'either': [402], 'for': [403, 455, 467], 'acquired': [404], 'resistance': [406], 'or': [407], 'earlier': [409], 'line.': [410], 'Citation': [411], 'Format:': [412], 'Taiguang': [413], 'Jimmy': [414], 'Jin,': [415], 'Sang-Uk': [416], 'Kang,': [417], 'Chulwon': [418], 'Kim,': [419], 'Jehrod': [420], 'Brenneman,': [421], 'Mihee': [422], 'Song,': [423], 'Pavel': [424], 'Printsev,': [425], 'Bo-Bae': [426], 'Seo,': [427], 'Yong-Hee': [428], 'Lee,': [429], 'Sang-Yoon': [430], 'Lee.': [431], 'BBT-207,': [432], 'novel,': [434], 'generation,': [436], 'epidermal': [437], 'factor': [439], 'receptor': [440], '(EGFR)': [441], 'tyrosine': [442], 'inhibitor': [444], '(TKI)': [445], '[abstract].': [460], 'In:': [461], 'Proceedings': [462], 'American': [465], 'Association': [466], 'Cancer': [468, 479], 'Research': [469], 'Annual': [470], 'Meeting': [471], '2022;': [472], '2022': [473], 'Apr': [474], '8-13.': [475], 'Philadelphia': [476], '(PA):': [477], 'AACR;': [478], 'Res': [480], '2022;82(12_Suppl):Abstract': [481], 'nr': [482], '3346.': [483]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4282916011', 'counts_by_year': [{'year': 2024, 'cited_by_count': 2}, {'year': 2023, 'cited_by_count': 2}, {'year': 2022, 'cited_by_count': 1}], 'updated_date': '2024-12-24T04:34:02.709716', 'created_date': '2022-06-16'}